Literature DB >> 7570610

Physiologically-based pharmacokinetic modeling and bioactivation of xenobiotics.

H J Clewell1, M E Andersen.   

Abstract

This paper describes the development and implementation of physiologically-based pharmacokinetic (PB-Pk) models to examine the disposition of xenobiotics and their bioactivation. In a PB-Pk model, the structure of the model is based, to as great extent as practicable, on the actual physiological and biochemical structure of the animal system being described. This paper provides an overview of the PB-Pk modeling approach using a series of models as examples. PB-Pk models for styrene and the dihalomethanes are discussed in relation to their ability to predict the kinetics of uptake, distribution, metabolism (bioactivation), and elimination in both rodents and humans. Three models are discussed which demonstrate the process of describing increasing complexity in bioactivation with reference to saturation of metabolism (methylene chloride), suicide enzyme inactivation (trans-1,2-dichloroethylene), and glutathione depletion (allyl chloride). Experimental studies to quantify these particular examples of non-linear kinetics were conducted by closed chamber gas uptake techniques. All of these behaviors can be quantitatively expressed within the framework of a PB-Pk model.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7570610     DOI: 10.1177/074823379401000101

Source DB:  PubMed          Journal:  Toxicol Ind Health        ISSN: 0748-2337            Impact factor:   2.273


  5 in total

Review 1.  Whole body pharmacokinetic models.

Authors:  Ivan Nestorov
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice.

Authors:  Javier Reig-López; María Del Mar Maldonado; Matilde Merino-Sanjuan; Ailed M Cruz-Collazo; Jean F Ruiz-Calderón; Victor Mangas-Sanjuán; Suranganie Dharmawardhane; Jorge Duconge
Journal:  Pharmaceutics       Date:  2020-10-15       Impact factor: 6.321

3.  A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment.

Authors:  Harvey J Clewell; Melvin E Andersen; Hugh A Barton
Journal:  Environ Health Perspect       Date:  2002-01       Impact factor: 9.031

4.  The application of global sensitivity analysis in the development of a physiologically based pharmacokinetic model for m-xylene and ethanol co-exposure in humans.

Authors:  George D Loizou; Kevin McNally; Kate Jones; John Cocker
Journal:  Front Pharmacol       Date:  2015-06-30       Impact factor: 5.810

5.  Development and Application of a Life-Stage Physiologically Based Pharmacokinetic (PBPK) Model to the Assessment of Internal Dose of Pyrethroids in Humans.

Authors:  Pankajini Mallick; Marjory Moreau; Gina Song; Alina Y Efremenko; Salil N Pendse; Moire R Creek; Thomas G Osimitz; Ronald N Hines; Paul Hinderliter; Harvey J Clewell; Brian G Lake; Miyoung Yoon
Journal:  Toxicol Sci       Date:  2020-01-01       Impact factor: 4.849

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.